Table 8.
Post sample preparation dilution study at 2-, 3-, 4-, and 5-fold using Mobile phase A.
| Morphine (n=3) | Morphine-3-β-Glucuronide (n=3) | Morphine-6-β-Glucuronide (n=3) | Hydromorphone (n=3) | Normorphine (n=3) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2-fold | 3-fold | 4-fold | 5-fold | 2-fold | 3-fold | 4-fold | 5-fold | 2-fold | 3-fold | 4-fold | 5-fold | 2-fold | 3-fold | 4-fold | 5-fold | 2-fold | 3-fold | 4-fold | 5-fold | |
| Mean | 81.2 | 80.8 | 81.0 | 80.4 | 89.8 | 87.0 | 86.4 | 87.8 | 86.5 | 86.7 | 89.3 | 89.4 | 88.8 | 88.6 | 88.4 | 87.6 | 92.0 | 93.1 | 100.0 | 95.5 |
| SD | 3.2 | 3.9 | 2.9 | 1.1 | 1.5 | 1.6 | 2.7 | 4.1 | 5.0 | 1.5 | 2.6 | 1.6 | 2.4 | 2.3 | 2.7 | 2.1 | 10.6 | 1.1 | 7.1 | 5.1 |
| %CV | 3.9% | 4.8% | 3.6% | 1.4% | 1.6% | 1.9% | 3.2% | 4.7% | 5.8% | 1.7% | 2.9% | 1.8% | 2.7% | 2.6% | 3.0% | 2.4% | 11.6% | 1.2% | 7.1% | 5.3% |
| Undiluted Observed Mean (n=12) | 81.4 | 88.5 | 89.2 | 87.3 | 93.5 | |||||||||||||||
| %Diff | −0.2% | −0.8% | −0.5% | −1.2% | 1.5% | −1.8% | −2.4% | −0.8% | −3.1% | −2.8% | 0.1% | 0.2% | 1.7% | 1.4% | 1.2% | 0.3% | −1.6% | −0.4% | 7.0% | 2.1% |